Aerami Therapeutics Announces Completion of Dosing in Phase 1 Trial of AER-901 (inhaled imatinib), a Crit
- AER-901 (inhaled imatinib), a potential reverse-remodeling therapy, is being developed to address unmet need for PAH treatments that target pulmonary vascular remodeling while supporting ease-of-use for patients.
- PAH is a rare and progressive disease with no cure; pulmonary vascular remodeling is believed to drive disease progression and poor outcomes, however, all currently approved therapies primarily mediate vasodilation.
- Aerami plans to advance AER-901 into a Phase 2 trial during the first half of 2023, following an amendment to the open AER-901 IND application with the U.S. Food and Drug Administration (FDA).
DURHAM, N.C., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Aerami Therapeutics Holdings, Inc ("Aerami"), a clinical stage biopharmaceutical company dedicated to breathing life into the treatment of serious cardiopulmonary and cardiometabolic conditions, today announced completion of dosing in a Phase 1 study of AER-901, a drug-device combination comprised of imatinib for inhalation and the FOX nebulizer.
Continue read on benzinga.com